Which medications in the drug class Phosphodiesterase (type 5) enzyme inhibitor are used in the treatment of Mixed Connective-Tissue Disease (MCTD)?

Updated: Jan 21, 2021
  • Author: Eric L Greidinger, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Phosphodiesterase (type 5) enzyme inhibitor

Phosphodiesterase inhibitors can ameliorate symptoms of pulmonary hypertension and Raynaud phenomenon in patients with MCTD. These agents may not be as durable as other drug classes in improving pulmonary hypertension, but the adverse-effect profile of phosphodiesterase inhibitors is often more favorable than that of prostaglandin or anti-endothelin therapies.


Promotes selective smooth-muscle relaxation in lung vasculature, possibly by inhibiting phosphodiesterase type 5 (PDE-5). This reduces pulmonary arterial pressure and increases cardiac output.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!